Soligenix announced that it has entered into an exclusive option agreement with Silk Road Therapeutics, a privately-held company. The option agreement grants the company the right to acquire a novel topical formulation of Pentoxifylline, a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patient’s suffering from Behcet’s Disease. BD is a rare multisystem inflammatory vasculitis with no cure, characterized by debilitating recurrent ulcers in the oral mucosa, skin/genitalia, and eye compartment. An orphan disease and area of unmet medical need affecting approximately 18,000 people in the United States and 80,000 in Europe, there are as many as 1,000,000 people worldwide living with this painful and life altering disease. Terms of the deal were not disclosed.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SNGX:
- Soligenix requests Type A meeting with FDA for Phase 3 HyBryte study in lymphoma
- Soligenix Shares Tumble as FDA Demands More Data
- Soligenix provides regulatory update on HyBryte
- Soligenix announces USAN approved “hypericin sodium” as name for new ingredient
- Soligenix announces Type A meeting with FDA for HyBryte NDA
